OGI - OrganiGram Holdings Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Moncton,
Canada
Type: Equity
OGI price evolution
OGI
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $79.26 | $71.8 | $33.9 | $33.9 |
| Short term investments | $0.81 | $0.8 | ||
| Net receivables | $29.93 | $29.19 | $30.2 | $30.2 |
| Inventory | $84.08 | $83.26 | $81 | $81 |
| Total current assets | $205.65 | $194.26 | $156 | $156 |
| Long term investments | $4.9 | $5.02 | $5.13 | |
| Property, plant & equipment | $95.44 | $97.12 | $99 | $99 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $354.75 | $331.78 | $298.5 | $298.5 |
| Current liabilities | ||||
| Accounts payable | $39.72 | $40.17 | $20 | $20 |
| Deferred revenue | ||||
| Short long term debt | $0.86 | $1.03 | $1.09 | |
| Total current liabilities | $47.9 | $56.03 | $22.4 | $22.4 |
| Long term debt | $2.47 | $3.18 | $3.6 | $3.6 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $58.89 | $59.98 | $26.8 | $26.8 |
| Shareholders' equity | ||||
| Retained earnings | -$578.54 | -$581.35 | -$505.1 | -$505.1 |
| Other shareholder equity | $36.66 | $35.81 | -$0.2 | -$0.2 |
| Total shareholder equity | $295.86 | $271.8 | $257.82 | |
| (in millions $) | 30 Oct 2023 | 31 Aug 2022 | 30 Aug 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.9 | $98.61 | $55.37 | $18.3 |
| Short term investments | $30.09 | $128.19 | $50 | |
| Net receivables | $30.2 | $46.37 | $21.29 | $12.63 |
| Inventory | $81 | $68.28 | $48.82 | $53.38 |
| Total current assets | $156 | $221.62 | $260.62 | $126.61 |
| Long term investments | $13.72 | $6.29 | $5.03 | $7 |
| Property, plant & equipment | $99 | $259.82 | $235.94 | $184.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $197.08 | |||
| Total investments | ||||
| Total assets | $298.5 | $577.11 | $554.02 | $323.69 |
| Current liabilities | ||||
| Accounts payable | $20 | $40.86 | $18.95 | $13.01 |
| Deferred revenue | ||||
| Short long term debt | $1.09 | $0.08 | $0.08 | $11.6 |
| Total current liabilities | $22.4 | $40.94 | $26.27 | $21.63 |
| Long term debt | $3.6 | $0.15 | $0.23 | $77.12 |
| Total noncurrent liabilities | $79.24 | |||
| Total debt | $91.23 | |||
| Total liabilities | $26.8 | $69.05 | $74.21 | $100.87 |
| Shareholders' equity | ||||
| Retained earnings | -$505.1 | -$261.59 | -$275.64 | -$107.82 |
| Other shareholder equity | -$0.2 | -$0.08 | $24.65 | $17.7 |
| Total shareholder equity | $271.62 | $508.06 | $479.81 | $299.53 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $41.06 | $37.63 | $46.04 | |
| Cost of revenue | $27.05 | $28.03 | ||
| Gross Profit | $14.01 | $9.6 | -$12.75 | |
| Operating activities | ||||
| Research & development | $2.46 | $2.61 | ||
| Selling, general & administrative | $16.6 | $21.97 | ||
| Total operating expenses | $46.11 | $52.6 | $26.68 | |
| Operating income | -$5.05 | -$14.98 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.03 | -$2.28 | ||
| Interest expense | -$0.05 | -$0.07 | $0.49 | |
| Net income | ||||
| Net income | $2.82 | -$27.08 | -$32.99 | |
| Income (for common shares) | $2.82 | -$27.08 | ||
| (in millions $) | 30 Oct 2023 | 31 Aug 2022 | 1 Oct 2021 | 30 Aug 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $161.6 | $145.81 | $86.8 | |
| Cost of revenue | $114.24 | $137.19 | ||
| Gross Profit | -$31 | $31.57 | -$50.4 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $59.77 | $44.52 | ||
| Total operating expenses | $90.8 | $174.01 | $186.44 | |
| Operating income | -$28.2 | -$99.64 | ||
| Income from continuing operations | ||||
| EBIT | -$99.64 | |||
| Income tax expense | -$3.8 | -$10.47 | ||
| Interest expense | $7.1 | -$5.18 | ||
| Net income | ||||
| Net income | -$248.6 | -$14.28 | -$136.16 | |
| Income (for common shares) | -$14.28 | -$136.16 | ||
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Net income | $2.82 | -$27.08 | ||
| Operating activities | ||||
| Depreciation | $2.25 | $1.56 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$3.73 | -$8.98 | ||
| Investing activities | ||||
| Capital expenditures | -$0.95 | -$0.45 | ||
| Investments | ||||
| Total cash flows from investing | -$14.87 | -$1.9 | $4.94 | $4.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $26.29 | $41.1 | ||
| Net borrowings | -$0.23 | -$0.24 | ||
| Total cash flows from financing | $26.06 | $40.86 | -$0.82 | -$0.82 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.45 | $29.99 | -$34.66 | -$34.66 |
| (in millions $) | 30 Oct 2023 | 31 Aug 2022 | 30 Aug 2021 | 30 Aug 2020 |
|---|---|---|---|---|
| Net income | -$14.28 | -$130.7 | -$136.16 | |
| Operating activities | ||||
| Depreciation | $22.26 | $30.89 | $17.76 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$36.21 | -$28.59 | -$45.13 | |
| Investing activities | ||||
| Capital expenditures | -$48.75 | -$11.79 | -$77.22 | |
| Investments | -$72.49 | -$49.87 | ||
| Total cash flows from investing | $4.94 | $44.03 | -$115.11 | -$138.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.43 | |||
| Net borrowings | -$1.01 | -$116.4 | $64.05 | |
| Total cash flows from financing | -$0.82 | $5.33 | $174.46 | $160.37 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$34.66 | $13.15 | $30.77 | -$22.95 |
News
Fundamentals
| Market cap | $161.93M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 103.80M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 25.24% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.62 |
| Book/Share | 2.50 |
| Cash/Share | 0.76 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.10 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.29 |
| Quick ratio | 2.54 |